Search
Now showing items 1-1 of 1
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
(SPRINGERNATURE, 2021-03-02)
BACKGROUND: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a ...